Praxis Precision Medicines PRAX
United StatesHealthcare · BiotechnologyUSD
644.42 USD (+131.8%)
19 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders, with no approved products or commercial revenue.
Key points
from its scores- ✓Good share-price trend9.8
- ✕Unfavourable risk and backdrop0.0
- ✕Little or no dividend0.5
- ✕Little competitive advantage0.8
AI analysis
bottom line, main risk, context and newsHigh speculative risk: only suitable for investors with high risk tolerance and a long-term horizon, betting on the success of its pipeline.
Praxis Precision Medicines is a development-stage biopharmaceutical company with no revenue, a healthy balance sheet (liquidity of 15.73) but an ROE of -38.86% and an operating margin of 0%. Its valuation depends entirely on the success of its pipeline, a high-risk binary event.
The main risk is regulatory: FDA approval of its drugs is uncertain, and any delay or rejection would have an existential impact on the company.
Context and risks
Development-stage biopharmaceutical company with no revenue or approved products, with an operating margin of 0% and an ROE of -38.86%. The main risk is regulatory: FDA approval of its drugs is uncertain, and any delay or rejection would have an existential impact. Additionally, the country of domicile (USA) presents a moderate governance risk.
Is Praxis Precision Medicines stock cheap or expensive?
at the analysis date| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 5.8 | 4.1 | +41% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 644.42 USD, +131.8% versus the price.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −29.8
- EV / EBITDA
- −18.5
- Price / book
- 5.8
- Market cap
- 7.8B USD
- Enterprise value
- 7.0B USD
Profitability
- ROE
- −38.9%
- ROA
- −25.7%
- Gross margin
- 0.0%
- Operating margin
- 0.0%
- Net margin
- 0.0%
- Free cash flow
- −199.4M USD
- FCF yield
- −2.6%
Solvency
- Total debt
- 1.1M USD
- Net debt
- −757.5M USD
- Cash
- 758.6M USD
- EBITDA
- −378.0M USD
- Net debt / EBITDA
- 2.00
- Debt / equity
- 0.08
- Current ratio
- 15.73
- Quick ratio
- 15.46
Growth
- EPS (TTM)
- −12.95 USD
- EPS (forward)
- −9.33 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 2.81
- Analyst consensus
- Strong buy (19)
- Target price
- 644.42 USD
- 52-week range
- 50.56 – 392.70
Recent news
All PRAX news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Praxis Precision Medicines
Is Praxis Precision Medicines stock cheap or expensive?
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 644.42 USD, +131.8% versus the price. This is not investment advice.
What score does Praxis Precision Medicines get on MeridIAn Screener?
It scores 2.1 out of 10, rank 2,120 of 2,130 (better than 0% of the companies analysed). Its strongest category is Momentum (9.8) and its weakest, Risk & Context (0.0). Analysis of 08/10/2026.
How much is Praxis Precision Medicines worth on the stock market?
Its market capitalisation is 7.8B USD and its enterprise value, debt included, is 7.0B USD.
How much debt does Praxis Precision Medicines have?
It has more cash than debt: net cash of 757.5M USD.
Does Praxis Precision Medicines pay a dividend?
It pays no dividend, or almost none.
How has Praxis Precision Medicines stock performed over the last year?
It has risen 422.0% over the last year, excluding dividends. Over the last 52 weeks it has traded between 50.56 and 392.70 USD. Past performance does not guarantee future results.
What do analysts think of Praxis Precision Medicines?
19 analysts cover it; their average recommendation is “Strong buy” and their average target is 644.42 USD (+131.8% versus the price). It is an estimate, not market data.